Literature DB >> 8580025

Frequently relapsing minimal change nephrotic syndrome with natural killer cell deficiency prior to the overt relapse of Hodgkin's disease.

T Mori1, A Yabuhara, J Nakayama, M Kitahara, K Washizawa, S Kasai, A Komiyama.   

Abstract

A 15-year-old boy developed minimal change nephrotic syndrome (MCNS) during remission of Hodgkin's disease. Natural killer (NK) cell activity was practically absent at the onset of MCNS, with a value of 3% compared with the normal value of 44.1% +/- 7.8% (mean +/- SD). Treatment with prednisolone resulted in transient remission of MCNS and partial improvement of NK cell activity. Extensive investigations for Hodgkin's disease were performed at 1- to 3-month intervals; a relapse finally became apparent 25 months after the diagnosis of MCNS. Successful treatment of Hodgkin's disease resulted in complete disappearance of proteinuria and normalisation of NK cell activity. Frequently relapsing MCNS with NK cells deficiency during remission of Hodgkin's disease appears to imply its subclinical relapse.

Entities:  

Mesh:

Year:  1995        PMID: 8580025     DOI: 10.1007/bf00860957

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  8 in total

1.  Nephrotic syndrome in Hodgkin's disease. Evidence for pathogenesis alternative to immune complex deposition.

Authors:  A V Moorthy; S W Zimmerman; P M Burkholder
Journal:  Am J Med       Date:  1976-10       Impact factor: 4.965

Review 2.  Glomerulopathies of neoplasia.

Authors:  J W Eagen
Journal:  Kidney Int       Date:  1977-05       Impact factor: 10.612

3.  Acute nephrotic syndrome as a manifestation of active Hodgkin's Disease. Report of four cases and review of the literature.

Authors:  J Plager; L Stutzman
Journal:  Am J Med       Date:  1971-01       Impact factor: 4.965

4.  Natural killing in normal children and children with Hodgkin's disease.

Authors:  H Kamiya; S Starr; B Lange
Journal:  Am J Pediatr Hematol Oncol       Date:  1985

5.  Nephrotic syndrome in Hodgkin's disease. Report of five cases and review of the literature.

Authors:  P Kramer; W Sizoo; E E Twiss
Journal:  Neth J Med       Date:  1981       Impact factor: 1.422

6.  Spontaneous and antibody-dependent cellular cytotoxicity by lymphocyte subpopulations in peripheral blood and spleen from adult untreated patients with Hodgkin's disease.

Authors:  S Gupta; G Fernandes
Journal:  Clin Exp Immunol       Date:  1981-07       Impact factor: 4.330

7.  Nephrotic syndrome in Hodgkins disease.

Authors:  F Walker; S O'Neill; M Carmody; W F O'Dwyer
Journal:  Int J Pediatr Nephrol       Date:  1983-03

8.  Natural killer cell immunodeficiency in siblings: defective killing in the absence of natural killer cytotoxic factor activity in natural killer and lymphokine-activated killer cytotoxicities.

Authors:  A Komiyama; H Kawai; A Yabuhara; M Yanagisawa; Y Miyagawa; M Ota; H Hasekura; T Akabane
Journal:  Pediatrics       Date:  1990-03       Impact factor: 7.124

  8 in total
  4 in total

1.  Hodgkin lymphoma and nephrotic syndrome in childhood.

Authors:  Piero Farruggia; Antonino Trizzino; Silvio Maringhini; Antonella Grigoli; Chiara Sapia; Mariella D'Alessandro; Serena Tropia; Paolo D'Angelo
Journal:  Indian J Pediatr       Date:  2010-09-25       Impact factor: 1.967

2.  Nephrotic syndrome and Hodgkin lymphoma in children. Report of two cases.

Authors:  A Pourtsidis; D Doganis; M Baka; M Varvoutsi; H Kosmidis
Journal:  Hippokratia       Date:  2014 Oct-Dec       Impact factor: 0.471

Review 3.  Rituximab in Minimal Change Disease: Mechanisms of Action and Hypotheses for Future Studies.

Authors:  Nima Madanchi; Martin Bitzan; Tomoko Takano
Journal:  Can J Kidney Health Dis       Date:  2017-03-13

4.  Association between childhood nephrotic syndrome and hemophagocytic lymphohistiocytosis.

Authors:  Daniel Landau; Evgenia Gurevich; Joseph Kapelushnik; Hannah Tamary; Ilan Shelef; Isaac Lazar
Journal:  Pediatr Nephrol       Date:  2013-08-15       Impact factor: 3.714

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.